Trial Profile
A Randomized, Multi-center, Single Dose, Cross over Study Comparing the Pharmacokinetic of Bio-similar EPTACOG Alfa with NOVOSEVEN®, in Patients with Congenital Factor VII Deficiency
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Eptacog alfa (Primary)
- Indications Factor VII deficiency
- Focus Pharmacokinetics
- Sponsors AryoGen Pharmed
- 03 Feb 2021 Status changed from recruiting to completed.
- 07 Jan 2021 Planned number of patients changed from 50 to 24.
- 07 Jan 2021 Planned End Date changed from 1 Oct 2020 to 25 Feb 2021.